LLY240719C965000
- 2.24
- -3.16-58.52%
Eli Lilly and Co Newsroom
Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS
Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >
Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS
Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 -7.76% Cantor Fitzgerald $885 → $885 Reiterates Overweight → Overweight 07/11/2024 4.22%
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Eli Lilly (LLY) has an average outperform rating and a price target range of $540 to $1,100, according to analysts polled by Capital IQ.Price: 955.75, Change: +5.29, Percent Change: +0.56
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Barclays analyst Carter Gould maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,025.According to TipRanks data, the analyst has a success rate of 59.5% and
Nomura maintains a 'buy' rating on Innovent Bio and raises the target price to HKD 55.87.
Nomura releases research report, maintaining a "buy" rating for Innovent Bio (01801), anticipating the company's sales will continue to grow healthily in the first half of the year, and the target price has been raised from HKD 55.31 to HKD 55.87. The bank stated that it adjusted Innovent Bio's sales forecasts for the next two years by 1% and 5%, respectively, to reflect the decline in sales of the BCMA multiple myeloma CAR-T therapy Fucaso, a cooperative project with Deerfield Capital, as well as the expectation of reduced sales of diabetes drug Mazdutide, co-developed with Eli Lilly and Co., due to increased market competition. Next year's sales forecast has been reduced from RMB 2.1 billion to 18 billion yuan.
Q2 Earnings Season Scorecard and Analyst Reports for Microsoft, Eli Lilly & UnitedHealth
The Zacks Research Daily presents the best research output of our analyst team.
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.The company is slated to report its second-
Eli Lilly and Co's Options: A Look at What the Big Money Is Thinking
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly and Co (NYSE:LLY).And retail traders should know.We noticed this today when the trades showed up on publicly available
Express News | Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Trump's Betting Election Odds Surge After Assassination Attempt, How Would The Market React?
On Saturday, Donald Trump was shot at a campaign rally in Pennsylvania, which could be a key moment that completely disrupts the US election landscape this year. Following the incident, data from Polymarket shows that Trump's chances of winning the election have skyrocketed to 71%.
Jim Cramer: Eli Lilly(LLY) on Path to $1 Trillion Market Cap as Alzheimer's Drug Can Be a 'Blockbuster'
Concept stocks take off across the board! Trump's company surged more than 70% before the market opened, and Tesla also soared!
I won!
The New Holy Grail for Weight-Loss Drugs Is Sleep Apnea -- WSJ
Whether millions of people will be able to afford one of the hot new weight-loss drugs could hinge on whether they cure the sleep apnea of people like Damon Sedgwick.
Obesity Market Will Become More Fragmented
0905 GMT - The obesity market is set to become more complex, with the current duopoly--Novo Nordisk and Eli Lilly--to be weakened, creating several more investment opportunities than currently
Eli Lilly & Co (LLY) Gets a Buy From Barclays
In a report released today, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,025.00. The company’s shares closed last Friday at $948.40.
Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
GLP-1 Concerns Clobbered This Healthcare Stock. Now It's Time to Buy.
ResMed makes its bank from products that battle sleep apnea. When that business seemed threatened, investors fled. Now it looks like they were too hasty. By Jacob Sonenshine ResMed is the latest